KR20210092719A - 신규 치료법 - Google Patents

신규 치료법 Download PDF

Info

Publication number
KR20210092719A
KR20210092719A KR1020217011245A KR20217011245A KR20210092719A KR 20210092719 A KR20210092719 A KR 20210092719A KR 1020217011245 A KR1020217011245 A KR 1020217011245A KR 20217011245 A KR20217011245 A KR 20217011245A KR 20210092719 A KR20210092719 A KR 20210092719A
Authority
KR
South Korea
Prior art keywords
oligonucleotide
patient
ulcerative colitis
weeks
remission
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217011245A
Other languages
English (en)
Korean (ko)
Inventor
아레주 자가리
퍼닐라 샌드월
샬롯 아드마이어
토마스 크니텔
피터 제르후니
Original Assignee
인덱스 파마슈티컬즈 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인덱스 파마슈티컬즈 아베 filed Critical 인덱스 파마슈티컬즈 아베
Publication of KR20210092719A publication Critical patent/KR20210092719A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020217011245A 2018-11-14 2019-11-14 신규 치료법 Ceased KR20210092719A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1818579.3 2018-11-14
GBGB1818579.3A GB201818579D0 (en) 2018-11-14 2018-11-14 New therapy
PCT/EP2019/081377 WO2020099585A1 (en) 2018-11-14 2019-11-14 New therapy

Publications (1)

Publication Number Publication Date
KR20210092719A true KR20210092719A (ko) 2021-07-26

Family

ID=64739449

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217011245A Ceased KR20210092719A (ko) 2018-11-14 2019-11-14 신규 치료법

Country Status (10)

Country Link
US (1) US20220218736A1 (https=)
EP (1) EP3880303A1 (https=)
JP (1) JP2022507493A (https=)
KR (1) KR20210092719A (https=)
CN (1) CN113226461A (https=)
AU (1) AU2019378077A1 (https=)
BR (1) BR112021005645A2 (https=)
CA (1) CA3118899A1 (https=)
GB (1) GB201818579D0 (https=)
WO (1) WO2020099585A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4147688A1 (en) 2021-09-09 2023-03-15 InDex Pharmaceuticals AB Enema formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
EP2596806A1 (en) * 2011-11-25 2013-05-29 Index Pharmaceuticals AB Method for prevention of colectomy
GB201707503D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New Therapy 3
GB201707500D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy
GB201707501D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy 2

Also Published As

Publication number Publication date
GB201818579D0 (en) 2018-12-26
BR112021005645A2 (pt) 2021-06-29
JP2022507493A (ja) 2022-01-18
WO2020099585A1 (en) 2020-05-22
US20220218736A1 (en) 2022-07-14
AU2019378077A1 (en) 2021-04-22
EP3880303A1 (en) 2021-09-22
CN113226461A (zh) 2021-08-06
CA3118899A1 (en) 2020-05-22

Similar Documents

Publication Publication Date Title
AU2023237033A1 (en) Cobitolimod for use in the treatment of inflammatory bowel disease
US11795462B2 (en) Therapy
EP3947685B1 (en) Oligonucleotide-based therapy for ulcerative colitis
KR20210092719A (ko) 신규 치료법
WO2018206713A1 (en) Cobitolimod for use in the treatment of inflammatory bowel disease
JP2023553336A (ja) 自己投与のためのコビトリモド用量
HK40059650B (en) Oligonucleotide-based therapy for ulcerative colitis
HK40059650A (en) Oligonucleotide-based therapy for ulcerative colitis

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210415

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20221111

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20250404

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250609

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D